APGE VS NAMS Stock Comparison

Performance

APGE
28/100

APGE returned -16.93% in the last 12 months. Based on SPY's performance of -13.93%, its performance is below average giving it a score of 28 of 100.

NAMS
10/100

NAMS returned -16.82% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Earnings

APGE
100/100

APGE has missed earnings 1 times in the last 20 quarters.

NAMS

"Earnings" not found for NAMS

Volatility

APGE
44/100

APGE has had a lower than average amount of volatility over the last 12 months giving it a score of 44 of 100.

NAMS
50/100

NAMS has had an average amount of volatility over the last 12 months giving it a score of 50 of 100.

Technicals

APGE

"Technicals" not found for APGE

NAMS
36/100

NAMS receives a 35 of 100 based on 14 indicators. 4 are bullish, 8 are bearish.

Profit

APGE

"Profit" not found for APGE

NAMS
15/100

Out of the last 9 quarters, NAMS has had 1 profitable quarters and has increased their profits year over year on 1 of them.

All score calculations are broken down here to help you make more informed investing decisions

Apogee Therapeutics, Inc. Common Stock Summary

Nasdaq / APGE

Healthcare

Biotechnology

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.

NewAmsterdam Pharma Company N.V. Ordinary Shares Summary

Nasdaq / NAMS

Healthcare

Biotechnology

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.

Power up your portfolio